Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.

Epicutaneous immunization is a potential non-invasive technique for antigen-specific immune-modulation. Topical application of protein antigens to barrier-disrupted skin induces potent antigen-specific immunity with a strong Th2-bias. In this study, we investigate whether the autoimmune inflammatory...

Full description

Bibliographic Details
Main Authors: Jessica Strid, Lee Aun Tan, Stephan Strobel, Marco Londei, Robin Callard
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2007-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC1849892?pdf=render
id doaj-ac7a2c634e64439d9a13f19aca1aa621
record_format Article
spelling doaj-ac7a2c634e64439d9a13f19aca1aa6212020-11-25T01:13:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032007-01-0124e38710.1371/journal.pone.0000387Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.Jessica StridLee Aun TanStephan StrobelMarco LondeiRobin CallardEpicutaneous immunization is a potential non-invasive technique for antigen-specific immune-modulation. Topical application of protein antigens to barrier-disrupted skin induces potent antigen-specific immunity with a strong Th2-bias. In this study, we investigate whether the autoimmune inflammatory response of chronic collagen-induced arthritis (CCIA) in DBA/1-TCR-beta Tg mice can be modified by epicutaneous immunization. We show that epicutaneous immunization with type II collagen (CII) inhibited development and progression of CCIA and, importantly, also ameliorated ongoing disease as indicated by clinical scores of disease severity, paw swelling and joints histology. Treated mice show reduced CII-driven T cell proliferation and IFN-gamma production, as well as significantly lower levels of CII-specific IgG2a serum antibodies. In contrast, CII-driven IL-4 production and IgE antibody levels were increased consistent with skewing of the CII response from Th1 to Th2 in treated mice. IL-4 production in treated mice was inversely correlated with disease severity. Moreover, T cells from treated mice inhibited proliferation and IFN-gamma production by T cells from CCIA mice, suggesting induction of regulatory T cells that actively inhibit effector responses in arthritic mice. The levels of CD4(+)CD25(+) T cells were however not increased following epicutaneous CII treatment. Together, these results suggest that epicutaneous immunization may be used as an immune-modulating procedure to actively re-programme pathogenic Th1 responses, and could have potential as a novel specific and simple treatment for chronic autoimmune inflammatory diseases such as rheumatoid arthritis.http://europepmc.org/articles/PMC1849892?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jessica Strid
Lee Aun Tan
Stephan Strobel
Marco Londei
Robin Callard
spellingShingle Jessica Strid
Lee Aun Tan
Stephan Strobel
Marco Londei
Robin Callard
Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.
PLoS ONE
author_facet Jessica Strid
Lee Aun Tan
Stephan Strobel
Marco Londei
Robin Callard
author_sort Jessica Strid
title Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.
title_short Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.
title_full Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.
title_fullStr Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.
title_full_unstemmed Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.
title_sort epicutaneous immunization with type ii collagen inhibits both onset and progression of chronic collagen-induced arthritis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2007-01-01
description Epicutaneous immunization is a potential non-invasive technique for antigen-specific immune-modulation. Topical application of protein antigens to barrier-disrupted skin induces potent antigen-specific immunity with a strong Th2-bias. In this study, we investigate whether the autoimmune inflammatory response of chronic collagen-induced arthritis (CCIA) in DBA/1-TCR-beta Tg mice can be modified by epicutaneous immunization. We show that epicutaneous immunization with type II collagen (CII) inhibited development and progression of CCIA and, importantly, also ameliorated ongoing disease as indicated by clinical scores of disease severity, paw swelling and joints histology. Treated mice show reduced CII-driven T cell proliferation and IFN-gamma production, as well as significantly lower levels of CII-specific IgG2a serum antibodies. In contrast, CII-driven IL-4 production and IgE antibody levels were increased consistent with skewing of the CII response from Th1 to Th2 in treated mice. IL-4 production in treated mice was inversely correlated with disease severity. Moreover, T cells from treated mice inhibited proliferation and IFN-gamma production by T cells from CCIA mice, suggesting induction of regulatory T cells that actively inhibit effector responses in arthritic mice. The levels of CD4(+)CD25(+) T cells were however not increased following epicutaneous CII treatment. Together, these results suggest that epicutaneous immunization may be used as an immune-modulating procedure to actively re-programme pathogenic Th1 responses, and could have potential as a novel specific and simple treatment for chronic autoimmune inflammatory diseases such as rheumatoid arthritis.
url http://europepmc.org/articles/PMC1849892?pdf=render
work_keys_str_mv AT jessicastrid epicutaneousimmunizationwithtypeiicollageninhibitsbothonsetandprogressionofchroniccollageninducedarthritis
AT leeauntan epicutaneousimmunizationwithtypeiicollageninhibitsbothonsetandprogressionofchroniccollageninducedarthritis
AT stephanstrobel epicutaneousimmunizationwithtypeiicollageninhibitsbothonsetandprogressionofchroniccollageninducedarthritis
AT marcolondei epicutaneousimmunizationwithtypeiicollageninhibitsbothonsetandprogressionofchroniccollageninducedarthritis
AT robincallard epicutaneousimmunizationwithtypeiicollageninhibitsbothonsetandprogressionofchroniccollageninducedarthritis
_version_ 1725161250948644864